Study Summary
Chimeric antigen receptor T cells (CAR-T cells) has been recognized a promising treatment option for treating B cell derived malignancy. The purpose of this study is to evaluate the efficacy and safety of third-generation anti-CD19 CAR T-cells (CD19-CAR-T2 Cells) in patients with CD19+ relapsed or refractory (r/r) B-cell acute lymphoblastic leukemia (B-ALL) and B-cell Non Hodgkin Lymphoma (B-NHL).
Want to learn more about this trial?
Request More InfoInterventions
CD19-CAR-T2 CellsBIOLOGICAL
CD19-CAR-T2 T cells will be infused over 10-15 minutes on Day 0.
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Nanfang Hospital, Southern Medical University | Guangzhou | Guangdong | China |